AHA 2005

Drug-eluting Stents: No Benefit in Vein Grafts

Drug-eluting stents should not be the favoured option for treating saphenous vein graft lesions according conclusions from a registry analysis presented to the American Heart Association conference by Jeff Trost from Johns Hopkins in Baltimore.

Click here for all the interviews from AHA 2005

Similar Interviews

  • Drug-eluting Stents: Cost-Benefit Targeting?
  • Matthias Pfisterer Drug-eluting stents and their additional benefit to low-risk patients were investigated in a cost-effectiveness analysis presented to the Stockholm

  • Audio Journal of Cardiovascular Medicine 12.1, January 2006
  • Reporting from: American Heart Association Annual Scientific Sessions November 13-16, 2005, Dallas In this edition: Bryan Williams told American Heart Association attendees that

  • Audio Journal of Cardiovascular Medicine: Patients with High Restenosis Risk Benefit More from Drug Eluting Stents">Audio Journal of Cardiovascular Medicine: Patients with High Restenosis Risk Benefit More from Drug Eluting Stents
  • Raul Moreno REFERENCE: Abstract 3103, European Society of Cardiology Congress, 2007, 1-5 September, Vienna, Austria

    Post a comment

    Subscribe to Audio Medica Podcast